contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


mendus-ab-publ-has-decided-on-directed-issues-of-class-c-shares-and-transfer-of-own-ordinary-shares

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

MFN – 5 May 25              Mendus AB (publ): Mendus strengthens late-stage clinical developmen...    Mendus AB ('Mendus' publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Me...                             Kovan tason rekry CMO:ksi Osake +22%

Inderes lopettaa Menduksen seurannan, koska yhtiö on päättänyt analyysisopimuksen. Mendus keskittyy AML-hoitoihin ja tähtää Phase III -vaiheeseen vuoteen 2025 mennessä. Ensimmäinen kaupallistaminen odotetaan vuonna 2029. Suurimmat riskit liittyvät rahoituksen varmistamiseen ja kliinisiin tuloksiin.                   Inderes              Mendus: We are discontinuing coverage - Inderes    We are discontinuing our coverage of Mendus as the company has terminated the equity research agreement. Consequently, we will no longer be giving a target price (was SEK 14) or a recommendation (was Accumulate) for the stock.

Mendus aloitti ilixadencelin uuden kliinisen tutkimuksen suunnittelun pehmytkudossarkoomaa vastaan ja eteni CADENCE-tutkimuksen potilashankinnassa. Kulusäästöjen ansiosta rahavaranto ulottuu nyt Q4’25 asti (aiemmin Q3’25). Alla on Antin näpyttelemä tuore yhtiöraportti Menduksesta.                    Inderes              Mendus Q3'24: Building basis for a pivotal trial - Inderes    In Q3, Mendus reported bringing ilixadencel back into clinical development, opening research centers for the CADENCE trial and progressing in building Phase III readiness.                             In Q3, Mendus reported bringing ilixadencel back into clinical development, opening research centers for the CADENCE trial and progressing in building Phase III readiness. Operating expenses for the quarter came in below our expectations due to implemented cost savings that should continue in the coming months. As a result, the company’s cash runway has been extended into Q4’25 (was Q3’25). We reiterate our target price of SEK 14 and lower our recommendation to Accumulate (was Buy) due to the stock price appreciation relative to our DCF model and Nordic immuno-oncology peers.

Pareto antanut ostosuosituksen tavoitehinnalla 14 kruunua:                  Affärsvärlden              Mendus stiger efter köp från Pareto | Affärsvärlden                              Kurssi +26,88%

Tässä on Antin yhtiöraportti Menduksen Q2:n jälkeen.  Mendukselle Q2/24 merkitsi ratkaisevan CADENCE-tutkimuksen alkua akuutissa myelooisessa leukemiassa (AML). Yhtiö ilmoitti myös suunnitelmista käynnistää uudelleen ilixadencelin kliininen kehitys pehmytkudossarkoomissa (STS). Samanaikaisesti Mendus valmistautuu ratkaisevaan AML-tutkimukseen vuoden 2025 jälkipuoliskolla. Näitä keskeisiä kehityskulkuja tukee turvattu rahoitus Q3/25 asti. Sisällytämme STS-indikaation arvioihimme ja tarkistamme T&K-kustannusarvioitamme ylöspäin tuleville vuosille. Toistamme suosituksemme (Osta) sekä tavoitehintamme 14 SEK, sillä sekä DCF-mallimme että vertailuarvostuksemme viittaavat osakkeen nousupotentiaaliin.  https://www.inderes.fi/research/mendus-q224-ilixadencel-to-return-to-the-clinical-arena

Mendus julkaisi toisen vuosineljänneksen raporttinsa perjantaina 23.8. Toimitusjohtaja Erik Manting tiivistää Antin haastattelussa, mitä tapahtui toisella neljänneksellä sekä kertoo CADENCE-tutkimuksen keskeiset saavutukset sekä kertoo uudesta Ilixadencel-lääkkeen tutkimuksesta.                   Inderes              Mendus Q2´24: The CADENCE trial has started - Inderes    Time: 23.08.2024 klo 15.42 Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with...                             Aiheet: 00:00 Start  00:14 What has happened during Q2  04:58 The CADENCE trial  08:04 Main milestones in CADENCE  09:36 Immune activation in AML patients - What have you learned?  12:19 New trial with Ilixadencel  15:16 Timeline for the trial  15:54 Building readiness in AML

Mendus

As authorized by shareholders at the Annual General Meeting on May 6, 2025, Mendus AB (publ) ("Mendus") has decided to issue and subsequently immediately repurchase Class C shares in order to...

<div class="mfn-preamble"><p><strong>As authorized by shareholders at the Annual General Meeting on May 6, 2025, Mendus AB (publ) ("Mendus") has decided to issue and subsequently immediately repurchase Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares.</strong></p></div><div class="mfn-body"><p>In order to offer remuneration to board members and bonuses to employees in shares, as well as to preserve liquidity, at the Annual General Meeting on May 6, 2025, Mendus shareholders authorized the board of directors of Mendus to decide on directed issues of redeemable and convertible Class C shares as well as repurchase of all issued Class C shares through a directed offer to all holders of Class C shares.</p><p>Pursuant to the authorizations granted by shareholders at the Annual General meeting on May 6, 2025, the board has resolved on two directed issues of a total of 1,725,000 Class C shares to DNB Bank ASA, Sweden Branch. The subscription price in the directed issues corresponds to the quota value of the shares, which is approximately SEK 1 per share. The board has also resolved, pursuant to the authorizations granted at the Annual General Meeting on May 6, 2025, to immediately repurchase all 1,725,000 Class C shares from DNB Bank ASA, Sweden Branch at the same price as the subscription price following completion of the issue of the Class C shares and registration at the Swedish Companies Registration Office.</p><p>The Class C shares that are repurchased will be converted into ordinary shares and subsequently transferred to the board members and employees who have chosen to receive their remuneration and bonuses in the form of shares. Payment of bonuses in shares to employees pertains to the financial year 2024 and will be delivered as soon as possible. Payment of remuneration in shares to board members pertains to the current term of office and will be delivered quarterly after the remuneration has been earned.</p><p>Mendus has previously not held any Class C shares or ordinary shares. After the share issue and subsequent conversion of all Class C shares to ordinary shares, the total number of ordinary shares in Mendus will amount to 52,084,578.</p></div><div class="mfn-footer mfn-contacts mfn-17d81f918f4c"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Erik Manting<br>Chief Executive Officer<br>E-mail: <a rel="noopener" href="mailto:ir@mendus.com">ir@mendus.com</a></p></div><div class="mfn-footer mfn-about mfn-868be8723f72"><p><strong class="mfn-heading-1">About Mendus AB (publ)</strong></p><p>Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <a rel="noopener" href="https://www.mendus.com/">https://www.mendus.com/</a> </p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/ba372955-f37c-4f1d-a983-5ab78c5133bd/mendus-ab-publ-has-decided-on-directed-issues-of-class-c-shares-and-transfer-of-own-ordinary-shares.pdf" class="mfn-generated mfn-primary">Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares</a></p></div>